Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Rigel Stories

2014-03-06 08:30:40

Initiates Phase 1 Trial for Intermittent Claudication SOUTH SAN FRANCISCO, Calif., March 6, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the American Journal of Physiology has published recent research results with its orally-bioavailable AMPK activator, R118. The publication, entitled "Exercise performance and peripheral vascular insufficiency improve with AMPK activation...", provides strong preclinical evidence that R118 may be useful in...

2014-02-27 08:29:32

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that company management will present at two upcoming investor conferences. Details of the events are as follows: Cowen and Company 34(th) Annual Health Care ConferenceDate - March 3, 2014 at 2:50 p.m. ETLocation - Boston, MAPresenter - Ryan Maynard, Executive Vice President and Chief Financial Officer 26(th) Annual ROTH ConferenceDate - March 11, 2014 at 2:00 p.m....

2014-02-06 08:28:15

SOUTH SAN FRANCISCO, Calif., Feb. 6, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at two investor conferences in New York City in February. Details of the presentations are as follows: 16(th) Annual BIO CEO & Investor ConferenceMonday, February 10 at 2:00 p.m. ET RBC Capital Markets Global Healthcare ConferenceTuesday, February...

2014-01-10 08:23:12

Earns $5.75M Milestone from AstraZeneca for Asthma Partnership SOUTH SAN FRANCISCO, Calif., Jan. 10, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present updated product development plans and a financial update at the upcoming 32(nd) Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16th at 9:00 a.m. PT (see webcast details below)....

2013-12-05 08:29:19

SOUTH SAN FRANCISCO, Calif., Dec. 5, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul R. Rodriguez, the company's president and chief operations officer, is scheduled to present a company overview at the Oppenheimer 24(th) Annual Healthcare Conference in New York City on Wednesday, December 11th at 2:10 p.m. ET. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website...

2013-11-05 08:34:07

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2013. For the third quarter of 2013, Rigel reported a net loss of $23.8 million, or $0.27 per share, compared to a net loss of $25.5 million, or $0.36 per share, in the same period of 2012. Weighted average shares outstanding for the third quarters of 2013 and 2012 were 87.4 million and 71.6...

2013-10-24 08:34:24

Path Forward Clear for Fostamatinib, Ends for R333 SOUTH SAN FRANCISCO, Calif., Oct. 24, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced updates on two of the Company's pipeline products: R333, a topical dermatological JAK/SYK inhibitor, and fostamatinib, an oral SYK inhibitor. R333 UpdateRigel announced that R333, which was being evaluated as a potential therapeutic for active skin lesions in patients with discoid lupus erythematosus (DLE), did...

2013-09-06 08:22:28

SOUTH SAN FRANCISCO, Calif., Sept. 6, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Stifel 2013 Healthcare Conference in Boston, MA on Thursday, September 12th at 1:30 p.m. ET. The presentation will be webcast live and can be accessed at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the...

2013-08-26 08:27:33

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R343, an inhaled SYK inhibitor being evaluated as a potential therapeutic for patients with allergic asthma, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study. The primary endpoint was the change in pre-bronchodilator FEV1 (a measure of lung function) from baseline to dosing completion at Week 8, comparing active doses...

2013-08-06 08:33:20

SOUTH SAN FRANCISCO, Calif., Aug. 6, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO) For the second quarter of 2013, Rigel reported a net loss of $22.8 million, or $0.26 per share, compared to a net loss of $24.7 million, or $0.35 per share, in the same period of 2012. Weighted average shares outstanding for the...